Published in J Urol on May 01, 2004
Percutaneous ablation in the kidney. Radiology (2011) 1.51
Feasibility and outcomes of repeat partial nephrectomy. J Urol (2008) 1.41
Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol (2009) 1.21
Multiple-electrode radiofrequency ablation creates confluent areas of necrosis: in vivo porcine liver results. Radiology (2006) 1.11
Microwave ablation versus radiofrequency ablation in the kidney: high-power triaxial antennas create larger ablation zones than similarly sized internally cooled electrodes. J Vasc Interv Radiol (2009) 1.04
Complications of radiofrequency ablation of hepatic, pulmonary, and renal neoplasms. Semin Intervent Radiol (2010) 0.96
Image guided tumour ablation. Cancer Imaging (2005) 0.89
Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol (2010) 0.87
Radiofrequency ablation and cryoablation of renal tumours. Curr Oncol (2007) 0.83
Complications of radiofrequency ablation of neoplasms. Semin Intervent Radiol (2006) 0.81
Use of bone wax during laparoscopic renal ablative procedures: optimizing port utilization and reducing tract-site exposure. JSLS (2008) 0.75
Feasibility and outcomes of laparoscopic renal intervention after prior open ipsilateral retroperitoneal surgery. J Endourol (2013) 0.75
Radiofrequency ablation: a nursing perspective. Clin J Oncol Nurs (2005) 0.75
Comparative Effects of Dexmedetomidine and Propofol on US-Guided Radiofrequency Ablation of Hepatic Neoplasm Under Monitored Anesthesia Care: A Randomized Controlled Study. Medicine (Baltimore) (2015) 0.75
Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol (1996) 3.93
Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology (2000) 2.92
The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol (2002) 2.48
Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology (2000) 2.15
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol (2002) 1.49
Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol (1992) 1.39
Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol (1997) 1.34
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Development of a radiofrequency based thermal therapy technique in an in vivo porcine model for the treatment of small renal masses. J Urol (2001) 1.00
Laparoscopic and computed tomography-guided percutaneous radiofrequency ablation of renal tissue: acute and chronic effects in an animal model. Urology (2001) 0.90
Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol (2003) 0.87
Radio frequency ablation of renal cell carcinoma: preliminary clinical experience. J Urol (2002) 0.86
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol (1992) 3.00
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology (2000) 2.15
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol (1990) 2.02
Vitamin D(3) in fat tissue. Endocrine (2008) 2.02
The lipids and fatty acid metabolism of photosynthetic bacteria. Biochim Biophys Acta (1965) 2.01
Hypopnea in sleep-disordered breathing in adults. Sleep (2001) 2.00
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
von Recklinghausen's disease and pheochromocytomas. J Urol (1999) 1.92
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Hereditary papillary renal cell carcinoma. J Urol (1994) 1.87
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab (2000) 1.80
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
The occurrence and biosynthesis of gamma-linolenic acid in a blue-green alga,Spirulina platensis. Lipids (1968) 1.75
A long-term follow-up of choroidal osteoma. Arch Ophthalmol (1998) 1.75
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med (1999) 1.65
Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med (1993) 1.65
Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia (2009) 1.65
Evaluation of the initial care of hypertensive patients. JAMA (1971) 1.64
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol (1996) 1.64
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol (2001) 1.61
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A (1995) 1.61
Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol (1995) 1.53
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52
Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol (1998) 1.51
Somatic allelic deletion of nm23 in human cancer. Cancer Res (1991) 1.50
Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res (2000) 1.50
Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst (1990) 1.49
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res (1998) 1.46
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
Laparoscopic adrenalectomy: a new standard of care. Urology (1997) 1.46
Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol (1984) 1.45
Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol (2001) 1.45
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Elevated HIV prevalence despite lower rates of sexual risk behaviors among black men in the District of Columbia who have sex with men. AIDS Patient Care STDS (2010) 1.44
Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol (1999) 1.41
Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. Cancer (1999) 1.39
Blindness from retrobulbar injection into the optic nerve. Ophthalmic Surg (1986) 1.39
Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery (1998) 1.38
Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res (1991) 1.38
Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene (1999) 1.38
Mantle oxidation state and its relationship to tectonic environment and fluid speciation. Science (1990) 1.35